Cellectar Biosciences (CLRB) said Wednesday the US Food and Drug Administration has granted breakthrough therapy designation to its experimental cancer drug, iopofosine I 131, for the treatment of relapsed or refractory Waldenstrom macroglobulinemia, a rare and currently incurable form of lymphoma.
The company said the designation was based on results from a phase 2 trial, where the drug achieved an 83.6% overall response rate and a 58.2% major response rate, significantly exceeding its 20% target.
Cellectar said it also submitted a data package to the European Medicines Agency to determine whether it can pursue conditional marketing authorization in the EU, adding that a recommendation on whether to proceed with a full application is expected by late July 2025.
Shares of the company were up more than 43% in Wednesday's premarket activity.
Price: 0.40, Change: +0.12, Percent Change: +43.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。